نتایج جستجو برای: nras

تعداد نتایج: 2055  

2013
Christian Posch Susana Ortiz-Urda

Mutations in the three rat sarcoma (RAS) family members NRAS (neuroblastoma-RAS), HRAS (Harvey-RAS) and KRAS (Kirsten-RAS) are found in one third of human cancers. Among the first oncogenes discovered in cutaneous melanoma was NRAS, which is mutant in up to 20% of tumors causing aberrant signaling in several downstream cascades. Despite, being a highly relevant therapeutic target, design of sma...

Journal: :Cancer Treatment Reviews 2021

Abstract Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy particularly challenging to treat. Although the development targeted as well immunotherapies led substantial improvement overall survival non-NRASmut (e.g. BRAFmut</...

2013
Kadoaki Ohashi Lecia V. Sequist Maria E. Arcila Christine M. Lovly Xi Chen Charles M. Rudin Teresa Moran David Ross Camidge Cindy L. Vnencak-Jones Lynne Berry Yumei Pan Hidefumi Sasaki Jeffrey A. Engelman Edward B. Garon Steven M. Dubinett Wilbur A. Franklin Gregory J. Riely Martin L. Sos Mark G. Kris Dora Dias-Santagata Marc Ladanyi Paul A. Bunn William Pao

Purpose:We sought to determine the frequency and clinical characteristics of patients with lung cancer harboringNRASmutations. We used preclinical models to identify targeted therapies likely to be of benefit against NRAS-mutant lung cancer cells. Experimental Design:We reviewed clinical data from patients whose lung cancers were identified at six institutions or reported in the Catalogue of So...

Journal: :Annals of Oncology 2023

Target therapy in metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant anti-EGFR treatment. RASgenes (KRAS+NRAS) are mutated 40-50% 5-10%; presence a double RAS is very rare phenomenon, which why mutations considered exclusive each other. Herein, we describe novel concomitant NRAS/BRAF series patients. A 800 carcinomas fixed...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Julie A Ellerhorst Victoria R Greene Suhendan Ekmekcioglu Carla L Warneke Marcella M Johnson Carolyn P Cooke Li-E Wang Victor G Prieto Jeffrey E Gershenwald Qingyi Wei Elizabeth A Grimm

PURPOSE NRAS and BRAF mutations are common in cutaneous melanomas, although rarely detected mutually in the same tumor. Distinct clinical correlates of these mutations have not been described, despite in vitro data suggesting enhanced oncogenic effects. This study was designed to test the hypothesis that primary human cutaneous melanomas harboring mutations in NRAS or BRAF display a more aggres...

2014
Igor Vujic Christian Posch Martina Sanlorenzo Adam J. Yen Aaron Tsumura Andrew Kwong Valentin Feichtenschlager Kevin Lai Douglas V. Arneson Klemens Rappersberger Susana M. Ortiz-Urda

Oncogenic mutations in the Neuroblastoma Rat Sarcoma oncogene (NRAS) are frequent in melanoma, but are also found in several other cancer types, such as lung cancer, neuroblastoma and colon cancer. We designed our study to analyze changes in NRAS mutant tumor cells derived from malignancies other than melanoma. A variety of small molecule inhibitors as well as their combinations was tested in o...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1988
A Neri D M Knowles A Greco F McCormick R Dalla-Favera

We investigated the frequency of mutations activating RAS oncogenes in human lymphoid malignancies, including B- and T-cell-derived acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. By the polymerase chain reaction/oligonucleotide hybridization method, DNA from 178 cases was analyzed for activating mutations involving codons 12 and 61 of the HRAS, KRAS and NR...

2015
Alessandra Ulivieri Giuseppe Cardillo Liborio Manente Gregorino Paone Andrea Petricca Mancuso Leonardo Vigna Enrico Di Stasio Rita Gasbarra Salvatore Girlando Alvaro Leone

BACKGROUND Melanoma is highly curable in early stages but holds devastating consequences in advanced phases with a median survival of 6-10 months. Lungs are a common metastasis target, but despite this, limited data are available on the molecular status of pulmonary lesions. MATERIALS AND METHODS 25 patients with surgically resected melanoma lung metastases were screened for BRAF, NRAS, CKIT ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Karen A Chernoff Lindsey Bordone Basil Horst Katherine Simon William Twadell Keagan Lee Jason A Cohen Shuang Wang David N Silvers Georg Brunner Julide Tok Celebi

PURPOSE Gain-of-function mutations in BRAF, NRAS, or KIT are associated with distinct melanoma subtypes with KIT mutations and/or copy number changes frequently observed among melanomas arising from sun-protected sites, such as acral skin (palms, soles, and nail bed) and mucous membranes. GAB2 has recently been implicated in melanoma pathogenesis, and increased copy numbers are found in a subse...

2016
Marieke I. G. Raaijmakers Daniel S. Widmer Apurva Narechania Ossia Eichhoff Sandra N. Freiberger Judith Wenzina Phil F. Cheng Daniela Mihic-Probst Rob Desalle Reinhard Dummer Mitchell P. Levesque

Acquired chemotherapeutic resistance of cancer cells can result from a Darwinistic evolution process in which heterogeneity plays an important role. In order to understand the impact of genetic heterogeneity on acquired resistance and second line therapy selection in metastatic melanoma, we sequenced the exomes of 27 lesions which were collected from 3 metastatic melanoma patients treated with ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید